echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > A complete analysis of the development of Shanghai's hospital drug market in 2020

    A complete analysis of the development of Shanghai's hospital drug market in 2020

    • Last Update: 2021-04-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical Network, March 24th, this issue of HMAS medical institution market analysis system in-depth deconstruction of the Shanghai hospital drug market in 2020: under the influence of the epidemic and large-scale procurement, how will the hospital market at all levels and categories perform in 2020?
     
    The tertiary hospital market scale is close to 50%
     
    According to statistics from the HMAS medical institution market analysis system, in 2020, the size of the Shanghai medical institution market will be close to 55 billion yuan.
    Among them, the first-tier hospital market accounted for 27%, the second-tier hospital market accounted for 24%, the third-tier hospital market accounted for 49%, and the third-tier hospital market accounted for about 5% compared to 2019.
     
    Figure 1 Market share of different levels of hospitals in Shanghai's hospital drug market in 2020
     
    The overall market size has declined slightly
     
    In 2020, the size of the Shanghai hospital market has declined due to the impact of the new crown epidemic.
    According to the statistics of the HMAS medical institution market analysis system, the size of the Shanghai hospital market in 2020 is 54.
    9 billion, suspending the rapid growth in recent years, compared with 2019 , A year-on-year decrease of 0.
    87%.
     
    Figure 2 2018-2020 Shanghai hospital drug market scale and growth performance
     
    The size of the secondary hospital market has shrunk significantly
     
    In 2020, the growth of the market size of hospitals at all levels is very different.
    The growth rate of first-level hospitals is 2.
    51%, slightly higher than the overall market; while the growth rate of second-level hospitals is -19.
    3%, which is a sharp drop from the growth of 21.
    75% in 2019.
    It is also the main reason why the overall market has stopped growing; the growth rate of tertiary hospitals is 9.
    63%, which is a significant increase in market share and growth rate compared to 2019.
     
      Figure 3 2019-2020 Shanghai hospital drug market different levels of hospital market growth performance
     
      Anti -tumor drug market leader in all categories
     
      In 2020, chemical drugs accounted for 75% of the hospital drug sales market in Shanghai, and proprietary Chinese medicines and biological preparations ranked second and third, accounting for 20% and 5%, respectively.
     
      Figure 4 The proportion of different drug categories in the Shanghai hospital drug market in 2020
     
      From the perspective of the treatment field, under the background of the overall market growth decline in 2020, half of the drug market size in the treatment field will show a negative growth.
    Among them, the treatment field with a relatively high market share such as anti-infection and respiratory system will decline to a large extent.
    Driven by the launch of innovative drugs and the rapid entry of medical insurance, anti-tumor drugs and immunomodulators are the fastest-growing therapeutic areas, followed by blood and hematopoietic organ drugs.
     
      Figure 5 The growth rate of different therapeutic areas in the Shanghai hospital drug market in 2020
      Medical Network, March 24th, this issue of HMAS medical institution market analysis system in-depth deconstruction of the Shanghai hospital drug market in 2020: under the influence of the epidemic and large-scale procurement, how will the hospital market at all levels and categories perform in 2020?
     
      The tertiary hospital market scale is close to 50%
     
      According to statistics from the HMAS medical institution market analysis system, in 2020, the size of the Shanghai medical institution market will be close to 55 billion yuan.
    Among them, the first-tier hospital market accounted for 27%, the second-tier hospital market accounted for 24%, the third-tier hospital market accounted for 49%, and the third-tier hospital market accounted for about 5% compared to 2019.
     
      Figure 1 Market share of different levels of hospitals in Shanghai's hospital drug market in 2020
     
      The overall market size has declined slightly
     
      In 2020, the size of the Shanghai hospital market has declined due to the impact of the new crown epidemic.
    According to the statistics of the HMAS medical institution market analysis system, the size of the Shanghai hospital market in 2020 is 54.
    9 billion, suspending the rapid growth in recent years, compared with 2019 , A year-on-year decrease of 0.
    87%.
     
      Figure 2 2018-2020 Shanghai hospital drug market scale and growth performance
     
      The size of the secondary hospital market has shrunk significantly
     
      In 2020, the growth of the market size of hospitals at all levels is very different.
    The growth rate of first-level hospitals is 2.
    51%, slightly higher than the overall market; while the growth rate of second-level hospitals is -19.
    3%, which is a sharp drop from the growth of 21.
    75% in 2019.
    It is also the main reason why the overall market has stopped growing; the growth rate of tertiary hospitals is 9.
    63%, which is a significant increase in market share and growth rate compared to 2019.
     
      Figure 3 2019-2020 Shanghai hospital drug market different levels of hospital market growth performance
     
      Anti -tumor drug market leader in all categories
     
      In 2020, chemical drugs accounted for 75% of the hospital drug sales market in Shanghai, and proprietary Chinese medicines and biological preparations ranked second and third, accounting for 20% and 5%, respectively.
     
      Figure 4 The proportion of different drug categories in the Shanghai hospital drug market in 2020
     
      From the perspective of the treatment field, under the background of the overall market growth decline in 2020, half of the drug market size in the treatment field will show a negative growth.
    Among them, the treatment field with a relatively high market share such as anti-infection and respiratory system will decline to a large extent.
    Driven by the launch of innovative drugs and the rapid entry of medical insurance, anti-tumor drugs and immunomodulators are the fastest-growing therapeutic areas, followed by blood and hematopoietic organ drugs.
     
      Figure 5 The growth rate of different therapeutic areas in the Shanghai hospital drug market in 2020
      Medical Network, March 24th, this issue of HMAS medical institution market analysis system in-depth deconstruction of the Shanghai hospital drug market in 2020: under the influence of the epidemic and large-scale procurement, how will the hospital market at all levels and categories perform in 2020?
     
      The tertiary hospital market scale is close to 50%
      The tertiary hospital market scale is close to 50%
     
      According to statistics from the HMAS medical institution market analysis system, in 2020, the size of the Shanghai medical institution market will be close to 55 billion yuan.
    Among them, the first-tier hospital market accounted for 27%, the second-tier hospital market accounted for 24%, the third-tier hospital market accounted for 49%, and the third-tier hospital market accounted for about 5% compared to 2019.
     
      Figure 1 Market share of different levels of hospitals in Shanghai's hospital drug market in 2020
      
     
      The overall market size has declined slightly
      The overall market size has declined slightly
     
      In 2020, the size of the Shanghai hospital market has declined due to the impact of the new crown epidemic.
    According to the statistics of the HMAS medical institution market analysis system, the size of the Shanghai hospital market in 2020 is 54.
    9 billion, suspending the rapid growth in recent years, compared with 2019 , A year-on-year decrease of 0.
    87%.
     
      Figure 2 2018-2020 Shanghai hospital drug market scale and growth performance
    Medicine, medicine, medicine
     
      The size of the secondary hospital market has shrunk significantly
      Two hospital hospital hospital market size significantly reduced
     
      In 2020, the growth of the market size of hospitals at all levels is very different.
    The growth rate of first-level hospitals is 2.
    51%, slightly higher than the overall market; while the growth rate of second-level hospitals is -19.
    3%, which is a sharp drop from the growth of 21.
    75% in 2019.
    It is also the main reason why the overall market has stopped growing; the growth rate of tertiary hospitals is 9.
    63%, which is a significant increase in market share and growth rate compared to 2019.
     
      Figure 3 2019-2020 Shanghai hospital drug market different levels of hospital market growth performance
     
      Anti -tumor drug market leader in all categories
      Anti- tumor tumor tumor drug market leader in all categories
     
      In 2020, chemical drugs accounted for 75% of the hospital drug sales market in Shanghai, and proprietary Chinese medicines and biological preparations ranked second and third, accounting for 20% and 5%, respectively.
     
      Figure 4 The proportion of different drug categories in the Shanghai hospital drug market in 2020
     
      From the perspective of the treatment field, under the background of the overall market growth decline in 2020, half of the drug market size in the treatment field will show a negative growth.
    Among them, the treatment field with a relatively high market share such as anti-infection and respiratory system will decline to a large extent.
    Driven by the launch of innovative drugs and the rapid entry of medical insurance, anti-tumor drugs and immunomodulators are the fastest-growing therapeutic areas, followed by blood and hematopoietic organ drugs.
     
      Figure 5 The growth rate of different therapeutic areas in the Shanghai hospital drug market in 2020
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.